Evolent Health, Inc. (NYSE:EVH) is on recovery track with 22.54% gain from a 1-year low price of $13.38. The company lost -4.71% to attain the price of $16.39 on 02/14/2019. Throughout the recent session, the prices were hovering between $16.24 and $17.17. These shares are 91.76% off its target price of $31.43 and the current market capitalization stands at $1.36B. The recent change has given its price a -13.48% deficit over SMA 50 and -43.58% deficit over its 52-week high. The stock witnessed -9.55% declines, -34.93% declines and -31.85% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found EVH’s volatility during a week at 3.33% and during a month it has been found around 3.83%.

Evolent Health, Inc. (EVH) Top Holders

Institutional investors currently hold around $1.44 billion or 0% in EVH stock. Look at its top three institutional owners. Capital Research Global Investors owns $131.45 million in Evolent Health, Inc., which represents roughly 9.67% of the company’s market cap and approximately 9.15% of the institutional ownership. Similar statistics are true for the second largest owner, Jpmorgan Chase & Co, which owns 7,116,321 shares of the stock are valued at $122.4 million. The third largest holder is Vanguard Group Inc, which currently holds $98.27 million worth of this stock and that ownership represents nearly 7.23% of its market capitalization.

Evolent Health, Inc. 13F Filings

At the end of September reporting period, 109 institutional holders increased their position in Evolent Health, Inc. (NYSE:EVH) by some 6,717,891 shares, 81 decreased positions by 6,717,177 and 28 held positions by 70,075,755. That puts total institutional holdings at 83,510,823 shares, according to SEC filings. The stock grabbed 36 new institutional investments totaling 1,365,991 shares while 25 institutional investors sold out their entire positions totaling 1,590,050 shares.

Evolent Health, Inc. (NYSE:EVH) Insider Trades

Multiple company employees have indulged in significant insider trading. Evolent Health, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that General Counsel Weinberg Jonathan has sold 15,000 shares of Evolent Health, Inc. (EVH) in trading session dated Sep. 13, 2018. These shares are worth $406,800 and were traded at $27.12 each. The SEC filing shows that Peterson Thomas Iii performed a sale of 70,000 shares. The COO disposed these shares by way of transaction on Sep. 13, 2018. The company’s shares were given away at $27.5 per share worth to an income of some $1,925,000 on account of Peterson Thomas Iii.

Chief Accounting Officer, Stone Lydia, sold 6,805 common shares of Evolent Health, Inc. (EVH) in the open market. In a transaction dated Aug. 30, 2018, the shares were put up for sale at an average price of $25, raking in a sum of $170,125. After this sale, 15,390 common shares of EVH are directly owned by the insider, with total stake valued at $252,242.

In the transaction dated Aug. 30, 2018, the great number of shares disposed came courtesy the COO; Peterson Thomas Iii disposed a total of 30,000 shares at an average price of $25, amounting to approximately $750,000. The insider now directly owns 67,868 shares worth $1,112,357.

Evolent Health, Inc. (EVH) Analyst Guide

Several analysts have released their opinion on Evolent Health, Inc. (NYSE:EVH), with 8 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.53 average brokerage recommendation.